NewsBenzinga礼来公布评估 Foundayo 疗效和安全性的 3 期 ACHIEVE-4 试验详细结果;与甘精胰岛素相比,Foundayo 的 MACE-4 风险降低 16%,MACE-3 风险降低 23%,达到非劣效性的主要目标 礼来公布评估 Foundayo 疗效和安全性的 3 期 ACHIEVE-4 试验详细结果;与甘精胰岛素相比,Foundayo 的 MACE-4 风险降低 16%,MACE-3 风险降低 23%,达到非劣效性的主要目标 Benzinga 2026.09.30 22:04 (GMT+0) Open on Benzinga Other news What Are Wall Street Analysts' Target Price for Lumentum Holdings Stock? Texas Pacific Land Stock: Analyst Estimates & Ratings Keybanc Reiterates Sector Weight on NVIDIAto Sector Weight Top 3 Tech Stocks That May Fall Off A Cliff This Month Truist Securities Maintains Hold on BILL Holdings, Raises Price Target to $66 Nvidia’s China Exit Could Trigger a Bull-Bear Showdown: 6 Leveraged ETFs to Watch Wednesday